Aggrenox Antitrust Investigation

Chimicles & Tikellis is investigating a potential class action lawsuit against Boehringer Ingelheim Pharmaceuticals (“Boehringer”) related to its branded drug Aggrenox.  Aggrenox is a capsule designed to prevent excessive blood clotting and reduce the risk of stroke.  In August of 2008, Boehringer entered into a settlement with the first company to develop a generic version of Aggrenox, whereby the generic agreed to forego market entry until July of 2015, and Boehringer agreed to make a substantial payment to the potential generic competitor.  C&T is investigating whether this agreement violates the antitrust laws.

If you have purchased Aggrenox and reside in one of the states listed below, please contact us via the “Email us about this Case” form:

  • Alabama
  • California
  • the District of Columbia
  • Florida
  • Guam
  • Hawaii
  • Illinois
  • Kansas
  • Massachusetts
  • Maine
  • Michigan
  • Minnesota
  • Mississippi
  • Nevada
  • New Hampshire
  • New Mexico
  • New York
  • North Dakota
  • Oregon
  • Utah
  • Vermont
  • Wisconsin

[accordion clicktoclose=”false”]
[accordion-item id=”item-1″ title=”Email us about this Case”]

[/accordion-item]
[accordion-item id=”item-2″ title=”Alert me to Case updates”]
[widgets_on_pages id=”Email Alerts”]
[/accordion-item]
[/accordion]